HIGHFDA DRUG

Zydus Lifesciences Chlorpromazine Hydrochloride 100 mg Recall 2025

Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. recall Chlorpromazine Hydrochloride Tablets, USP, 100 mg, 100-count bottles distributed nationwide in the United States. The recall stems from CGMP deviations that allowed N-Nitroso Desmethyl Chlorpromazine to exceed the acceptable intake limit. Health care providers and patients should stop using the product and contact the manufacturer

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
September 3, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
September 3, 2025
Hazard Level
HIGH
Brands
Zydus Lifesciences, Zydus Pharmaceuticals
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Zydus Lifesciences, Zydus Pharmaceuticals
Product type
Chlorpromazine Hydrochloride Tablets
Model numbers
Z305079, Z305080, Z305454, Z305455, Z305457, Z400492, Z400493, Z400494 +7 more
UPC codes
70710-1129, 70710-1130, 70710-1131, 70710-1132, 70710-1133, 70710-1129-1, 70710-1129-2, 70710-1129-4 +7 more
Sold at
Multiple Retailers
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    September 3, 2025

  2. Reported by FDA DRUG

    September 17, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A

About This Product

Chlorpromazine hydrochloride is an antipsychotic medication used to treat certain psychiatric conditions. It is distributed as a prescription drug and requires pharmacy verification.

Why This Is Dangerous

N-Nitroso Desmethyl Chlorpromazine is a nitrosamine impurity. Exposure levels above the acceptable intake limit may pose health risks over time.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Patients must stop using the affected product and seek medical guidance. The recall may require medical substitution and monitoring.

Practical Guidance

How to identify if yours is affected

  1. Identify the product by NDC 70710-1132-1
  2. Check model numbers listed in recall materials
  3. Confirm distributor as Zydus Pharmaceuticals (USA) Inc.

Where to find product info

NDC is printed on the bottle label. Recall pages and the FDA enforcement report provide model lists and guidance.

What timeline to expect

No refunds are specified for prescription drug recalls. Substitutions or guidance will be provided by the manufacturer and clinicians; timelines vary.

If the manufacturer is unresponsive

  • File a consumer complaint with the FDA if the company is unresponsive
  • Consult your clinician for safe alternatives and escalation as needed

How to prevent similar issues

  • Purchase prescription meds only from licensed pharmacies
  • Verify NDC and batch information before taking any drug
  • Monitor for adverse effects and report to a clinician immediately
  • Keep recall information for future reference

Documentation advice

Keep the product, packaging, recall notice, and any correspondence with the manufacturer or physician for records

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Model numbers affected include Z305079, Z305080, Z305454, Z305455, Z305457, Z400492, Z400493, Z400494, Z401158, Z401725, Z401726, Z404118, Z404119, Z404120, Z405648. Sold nationwide in the USA as 100-count bottles of 100 mg chlorpromazine hydrochloride tablets. Sold as Rx only. NDC: 70710-1132-1. Manufacturer: Zydus Lifesciences Ltd. (Baddi, India). Distributed by Zydus Pharmaceuticals (USA) Inc. (Pennington, NJ 08534). Recall date: 2025-09-03.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • Manufactured in India by Zydus Lifesciences
  • Distributed nationwide in the USA by Zydus Pharmaceuticals (USA) Inc.
  • Recall initiated 2025-09-03; status ACTIVE
  • Hazard: CGMP deviations with elevated N-Nitroso Desmethyl Chlorpromazine
  • No reported injuries or incidents at this time

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
POISONINGOTHER

Product Classification

Product Details

Model Numbers
Z305079
Z305080
Z305454
Z305455
Z305457
+10 more
UPC Codes
70710-1129
70710-1130
70710-1131
+12 more
Affected States
ALL
Report Date
September 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
HIGH

Zydus Pharmaceuticals Recalls Icosapent Ethyl Capsules Over Subpotency

Subpotent Drug: Due oxidation caused by leakage of the contents of the Icosapent Ethyl 1g capsules. Use of the affected product may lead to inconsistent therapeutic effects and an increase in potential gastrointestinal side effects in some patients.

Zydus Pharmaceuticals
Subpotent Drug:
Read more